When Patients Win, We All Win

Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects

EXPLORE OUR CLINICAL TRIALS


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

December 5, 2016

Innovative Combination Strategies: Oncolytic and Systemic Therapy

In a presentation given at Melanoma Bridge 2016, Dr. Sanjiv S. Agarwala discusses clinical data on oncolytic agents currently being investigated both as monotherapies and in combination with other agents for the treatment of melanoma.

November 11, 2016

Webcast: 2016 Third Quarter Business Update Conference Call on Monday at 4 PM Easter Standard Time

Provectus will hold its 2016 third quarter business update conference call on November 14, 2016 at 4 p.m. (EST).

October 18, 2016

Promising Results for Three Intralesional Oncolytic Agents

In a video appearing on P&T Community, Robert H. I. Andtbacka, MD, of the Huntsman Cancer Institute in Utah, reports on three oncolytic immunotherapy studies involving intralesional agents.

October 18, 2016

Provectus stock suspended from NYSE - Knoxville News Sentinel Interview with Interim CEO Peter Culpepper

October 12, 2016

Small Cap Nation Interviews Peter Culpepper

Small Cap Nation's Joya Dass sits down with interim CEO Peter Culpepper to discuss Provectus and its future outlook.

September 6, 2016

12th Congress of the European Association of Dermato-Oncology Presentation Slides Available

Dr. Sanjiv Agarwala presented at the 16th World Congress on Cancers of the Skin/12th Congress of the European Association of Dermato-Oncology in Vienna, Austria.

August 10, 2016

Webcast: Q2 2016 Quarterly Business Update Conference Call

Provectus will hold its 2016 second quarter business update conference call on August 10, 2016 at 4 p.m. (EDT).

July 11, 2016

Intralesional agents show promise in melanoma but may serve 'narrow clientele'

An article appearing in Healio's HemOnc Today discusses promising clinical results of PV-10 and other intratumoral agents that are being investigated for the treatment of melanoma, including combination therapies that are being investigated, such as PV-10 with pembrolizumab.

July 7, 2016

HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting

An article appearing in the Conference News section of Oncology News Magazine (Vol. 11, Issue 3) covers the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting.

June 8, 2016

2016 BIO International Convention Presentation Slides Available

Provectus presented at the 2016 BIO International Convention in San Francisco on June 8, 2016.

June 6, 2016

A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach

An article appearing on CancerNetwork discusses Dr. Sanjiv Agarwala's review of intralesional therapies for melanoma publishd in the May 2016 edition of Oncology.

June 2, 2016

Webcast: 2016 Marcum Microcap Conference Presentation

Provectus presented at the 2016 Marcum Microcap Conference in New York on June 2, 2016.

May 18, 2016

CHINABIO Partnering Forum 2016 Presentation Slides Available

Peter Culpepper, COO and interim CEO, presented at CHINABIO Partnering Forum 2016 in Suzhou, China on May 18, 2016.

May 16, 2016

Video: SNNLive Interviews Peter Culpepper at Growth Capital Expo 2016

SNNLive interviews Peter Culpepper at Growth Capital Expo 2016.

May 10, 2016

Webcast: Q1 2016 Quarterly Business Update Conference Call

Provectus will hold its 2016 first quarter business update conference call on May 10, 2016 at 4 p.m. (EDT).

May 5, 2016

Video: Peter Culpepper Interviewed at the Vatican's 2016 Cellular Horizons Conference

Peter Culpepper, interim CEO + COO, discussed Provectus' investigational cancer drug PV-10 during an interview at the Vatican's 2016 Cellular Horizons Conference.

May 4, 2016

Growth Capital Expo 2016 Presentation Webcast and Slides Available

Slides from the presentation at Growth Capital Expo 2016 are now available.

April 12, 2016

Developments in Intralesional Therapy for Metastatic Melanoma

An article appearing in Cancer Control summarizes relevant medical literature regarding the use of intralesional therapies in metastatic melanoma.

April 6, 2016

The Checkpoint Immunotherapy Revolution

Provectus will hold its quarterly year-end 2015 financial business update conference call at 4 p.m. (EDT) March 30, 2016.

March 30, 2016

Webcast: Quarterly Year-End 2015 Financial Business Update Conference Call

Provectus will hold its quarterly year-end 2015 financial business update conference call at 4 p.m. (EDT) March 30, 2016.

more...

PRESS RELEASES

November 30, 2016

Provectus Biopharmaceuticals, Inc. Announces Notification of NYSE MKT Listing Deficiency

Provectus today announced receipt of notification (the "Deficiency Letter") from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders' equity.

November 14, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Society for Immunotherapy of Cancer 2016 Annual Meeting

Provectus today announced the presentation of data on PV-10 at the Society for Immunotherapy of Cancer 2016 Annual Meeting.

November 10, 2016

Provectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results

Provectus today announced its financial results for the quarter ended September 30, 2016.

November 2, 2016

Provectus Biopharmaceuticals Announces Data on PV-10 for Treatment of Pancreatic Cancer Scheduled for Poster Presentation at 31st SITC Annual Meeting

Provectus today announced that researchers will present data on the treatment of pancreatic cancer with PV-10, an investigational ablative immunotherapy under development by Provectus for solid tumor cancers, at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

October 27, 2016

Provectus Biopharmaceuticals to Present at Sidoti's Fall 2016 Emerging Growth Conference, November 1, 2016

Provectus today announced that it will present at Sidoti and Company's Fall 2016 Emerging Growth Conference.

October 25, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 Third Quarter Business Update Conference Call on Monday, November 14, 2016, at 4 PM Eastern Standard Time

Provectus announced today that it will host its 2016 third quarter business update conference call on Monday, November 14, 2016 at 4 pm Eastern Standard Time.

October 14, 2016

Trading in Provectus Biopharmaceuticals Common Stock and Warrants Suspended by NYSE MKT

Provectus today confirmed that the Company received a notice dated October 13, 2016 from the staff of NYSE Regulation, Inc. ("NYSE Regulation") indicating that it has determined to suspend trading of the Company's common stock trading under the symbol "PVCT" and its class of warrants trading under the symbol "PVCTWS" immediately and to commence proceedings to delist the Company's common stock and warrants from NYSE MKT LLC ("NYSE MKT").

October 11, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at European Society of Medical Oncology 2016 Congress Now Available Online

Provectus today announced that the poster presented at the European Society of Medical Oncology 2016 Congress is now available online.

October 6, 2016

Provectus Biopharmaceuticals Files Registration Statement for Rights Offering to Existing Stockholders

Provectus today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing stockholders.

September 27, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at 31st SITC Annual Meeting

Provectus today announced that the Society for Immunotherapy of Cancer has accepted an abstract for a poster presentation related to the use of PV-10, an investigational ablative immunotherapy under development by Provectus for solid tumor cancers, in the treatment of pancreatic cancer.

September 8, 2016

Provectus Biopharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference

Provectus today announced that it will present at Rodman & Renshaw's 18th Annual Global Investment Conference.

August 30, 2016

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

Provectus today announced that it has completed its public offering of 240,000 shares of Series B Convertible Preferred Stock and warrants to purchase 24,000,000 shares of common stock at a price to the public of $25.00 for a combination of one share of Series B Convertible Preferred Stock and 100 warrants to purchase one share of common stock each.

August 25, 2016

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million

Provectus today announced the pricing of a "best efforts" public offering of 240,000 shares of Series B Convertible Preferred Stock.

August 24, 2016

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants

Provectus today announced that it intends to offer and sell shares of its Series B Convertible Preferred Stock and warrants to purchase common stock, subject to market and other conditions, in a "best efforts" public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.

August 23, 2016

Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs

Provectus today announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

August 9, 2016

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Provectus today announced its financial results for the quarter ended June 30, 2016.

August 1, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress

Provectus today announced that a poster presentation titled "Intralesional rose bengal for stage III and IV melanoma" is to be presented at the European Society for Medical Oncology 2016 Congress on October 9, 2016, in Hall E of the Bella Center in Copenhagen, Denmark.

July 20, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, August 10, 2016, at 4 PM Eastern Daylight Time

Provectus announced today that it will host its 2016 second quarter business update conference call on Wednesday, August 10, 2016 at 4 pm Eastern Daylight Time.

July 18, 2016

Provectus Biopharmaceuticals Receives Patent Allowance for Use of Halogenated Xanthenes in Pharmaceutical Compositions and as Medicaments

Provectus today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The allowed claims cover use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

July 14, 2016

Provectus Biopharmaceuticals Establishes Australian Subsidiary

Provectus today announced that it has formed an Australian subsidiary, Provectus Biopharmaceuticals Australia Pty Ltd. In addition, the Company is opening a Sydney office in New South Wales.

more...